Dr. Ilya Reyter, MD

Dr. Reyter practices at Surgery Center at the American Skin Institute in Sherman Oaks, California.

Dr. Reyter's NPI, 1558456517, was assigned on October 4, 2006. Dr. Reyter graduated from UCSF School of Medicine in 2001. Dr. Reyter holds California license A79982.

Dr. Reyter's primary practice is Surgery Center at the American Skin Institute, at 4836 Van Nuys Blvd, Sherman Oaks, CA 91403. The practice phone is (818) 907-7546.

Dr. Reyter's primary practice is Surgery Center at the American Skin Institute in Sherman Oaks, California. The medical group on file is American Skin Institute. Dmand AI also links Dr. Reyter to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reyter practices, 2 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Reyter's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Reyter is board certified in dermatology by the American Board of Dermatology. Dr. Reyter is licensed in California.

Dmand AI lists acute skin infection, benign or precancerous skin growths, contact dermatitis, itchy rashes, minor injury to a limb, rash, scalp rash and shingles among the conditions Dr. Reyter treats.

CMS data shows 5,731 Medicare services from Dr. Reyter across 29 procedure codes in 2024, for 540 Medicare patients. Medicare paid $361,429 for them.

CMS counts 540 Medicare patients who saw Dr. Reyter in 2024. The largest group is 65 to 74, with 228 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Reyter's median patient age at 72, with 49% women.

In 2024, Dr. Reyter wrote 136 Medicare Part D claims for 90 patients. 94% of them were for generic drugs. CMS names the drug for 52 of them, across 2 drugs with 11 or more claims each, at $620 in total drug cost. In 2023, CMS named 49 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Reyter for performance year 2024, reported as part of a group. Dr. Reyter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Reyter as offering telehealth. CMS counts 114 procedures of melanoma (skin cancer) excision by Dr. Reyter, more than 94% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Reyter. Dr. Reyter's most frequent co-author is Jacqueline Chloe Dolev, MD.

CMS Open Payments shows 300 general payments to Dr. Reyter from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 58% of the total. iCAD, Inc paid the most, $4,813.

Dmand AI lists 3 awards for Dr. Reyter, most recently Regional Top Doctor in 2014.

Dr. Reyter graduated from UCSF School of Medicine in 2001. Dr. Reyter is a member of AAD.

Dr. Reyter is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.